Latest news
{{'Thu, 02 Apr 2026 08:00:00 -0400' | dateFormatUsFilter}}
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
Read more
{{'Tue, 31 Mar 2026 07:46:00 -0400' | dateFormatUsFilter}}
Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year
Read more
{{'Thu, 26 Mar 2026 19:52:00 -0400' | dateFormatUsFilter}}
FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Read more
Latest on compounded and counterfeit products and other important information about semaglutide.